| A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | Datopotamab deruxtecan | Phase 2 | Not yet recruiting | AstraZeneca | Nov 17, 2026 |
| A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 2 | Not yet recruiting | Korea University Anam Hospital | Nov 17, 2026 |
| A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients | Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Centre Leon Berard | Nov 13, 2026 |
| Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 2 | Recruiting | Giselle Sholler | Nov 12, 2026 |
| Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 1 / Phase 2 | Recruiting | Txinno Bioscience Inc. | Nov 12, 2026 |
| A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig | Topotecan | Phase 3 | Not yet recruiting | Boehringer Ingelheim | Nov 10, 2026 |
| A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Topotecan | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Nov 9, 2026 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 4, 2026 |
| A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors | Exatecan | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Nov 4, 2026 |
| A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 1 / Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Nov 3, 2026 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 3, 2026 |
| A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 1 / Phase 2 | Not yet recruiting | Daniel Nussbaum, M.D. | Oct 29, 2026 |
| Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN) | Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria Careggi | Oct 29, 2026 |
| Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study | Irinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECIN | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Oct 27, 2026 |
| Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer | Exatecan | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oct 23, 2026 |
| A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | Datopotamab deruxtecan | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | Oct 22, 2026 |
| Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities | Topotecan | Phase 1 | Recruiting | Beijing Tongren Hospital | Oct 22, 2026 |
| TROPION Breast Respond in 1L TNBC | Datopotamab deruxtecan | — | Not yet recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Oct 9, 2026 |
| Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) | Topotecan | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | Oct 7, 2026 |
| Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors | Irinotecan sucrosofate | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | Sep 25, 2026 |
| A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Fujian Medical University | Sep 23, 2026 |
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | Exatecan | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | Sep 21, 2026 |
| Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan | Trastuzumab deruxtecan | Phase 3 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | Sep 18, 2026 |
| Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | Datopotamab deruxtecan, Sacituzumab govitecan, Trastuzumab deruxtecan | Phase 2 | Not yet recruiting | Fudan University | Sep 17, 2026 |
| Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | Sacituzumab govitecan | Phase 2 | Recruiting | Shanghai Chest Hospital | Sep 10, 2026 |
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy | Irinotecan sucrosofate | Phase 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | Sep 4, 2026 |
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer | Topotecan | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Sep 1, 2026 |
| Sacituzumab Govitecan and Q901 in Advanced TNBC | Sacituzumab govitecan | Phase 2 | Not yet recruiting | Yonsei University | Aug 26, 2026 |
| Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer | Trastuzumab deruxtecan | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | Aug 25, 2026 |
| Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies | Irinotecan sucrosofate | Phase 1 | Not yet recruiting | National Health Research Institutes, Taiwan | Aug 24, 2026 |
| A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer | Trastuzumab deruxtecan | Not applicable | Not yet recruiting | Shuangyue Liu | Aug 24, 2026 |
| A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | Sacituzumab govitecan | Phase 2 | Not yet recruiting | Shanghai East Hospital | Aug 21, 2026 |
| A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | Exatecan | Phase 1 / Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Aug 4, 2026 |
| GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | Datopotamab deruxtecan | Phase 1 / Phase 2 | Not yet recruiting | Eddingpharm (Zhuhai) Co., Ltd. | Jul 31, 2026 |
| SMP-656 for HER2-Positive Advanced Breast Cancer | Trastuzumab deruxtecan | Phase 2 | Recruiting | Chengdu SciMount Pharmatech Co., Ltd. | Jul 24, 2026 |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | Datopotamab deruxtecan | Phase 3 | Recruiting | AstraZeneca | Jul 22, 2026 |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Topotecan | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Jul 16, 2026 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer | Patritumab deruxtecan | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | Jul 14, 2026 |
| A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | Exatecan | Phase 1 / Phase 2 | Recruiting | SOTIO Biotech a.s. | Jul 9, 2026 |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | Sacituzumab govitecan | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | Jun 29, 2026 |
| Optimal Application Timing of ADC Drugs for Advanced Breast Cancer | Sacituzumab govitecan | Phase 2 | Recruiting | Liaoning Cancer Hospital & Institute | Jun 18, 2026 |
| Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma | Irinotecan sucrosofate | Phase 2 | Active, not recruiting | Tianjin Medical University Cancer Institute and Hospital | Jun 15, 2026 |
| Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids | Sacituzumab govitecan | — | Recruiting | Guangzhou Institute of Respiratory Disease | May 28, 2026 |
| An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China | Topotecan | Phase 3 | Recruiting | Genmab | May 22, 2026 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | Irinotecan sucrosofate | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | May 18, 2026 |
| Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response | Datopotamab deruxtecan, Sacituzumab govitecan | — | Recruiting | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | May 13, 2026 |
| A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | Irinotecan sucrosofate | Phase 2 / Phase 3 | Not yet recruiting | Hebei Medical University Fourth Hospital | May 13, 2026 |
| Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | Irinotecan sucrosofate | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | May 6, 2026 |
| A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | Exatecan | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | Apr 24, 2026 |
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression | Topotecan | Phase 3 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Apr 22, 2026 |
| Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study | Irinotecan sucrosofate | Phase 2 | Recruiting | Ningbo Medical Center Lihuili Hospital | Apr 21, 2026 |
| SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates | Datopotamab deruxtecan | Phase 2 | Recruiting | Jules Bordet Institute | Mar 16, 2026 |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Exatecan | Phase 1 | Recruiting | Avacta Life Sciences Ltd | Mar 6, 2026 |
| Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Exatecan | Phase 1 | Recruiting | EMD Serono Research & Development Institute, Inc. | Jan 22, 2026 |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | Patritumab deruxtecan | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | Dec 16, 2025 |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Patritumab deruxtecan | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | Jul 11, 2025 |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Patritumab deruxtecan | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | Apr 23, 2025 |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | Patritumab deruxtecan | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | Jan 28, 2025 |
| A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | Patritumab deruxtecan | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | Dec 13, 2024 |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | Patritumab deruxtecan | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | Nov 13, 2024 |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Patritumab deruxtecan | Phase 1 / Phase 2 | Active, not recruiting | Merck Sharp & Dohme LLC | Sep 19, 2024 |